Key facts
- It has raised $17.1M across 2 recorded rounds; the latest was Early Stage VC ($5.8M) in Sep 2024.
- Notable investors include Eli Lilly and Company Foundation, Formation Venture Engineering, Kenneth Lehman, Marc Chan, National Institutes of Neurological Disorders and Stroke — 6 tracked in total.
- Amprion has filed 3 Form Ds with the SEC since 2022, most recently Sep 2024 ($5.8M sold to 7 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 2 rounds
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Amprion
Funding rounds
2 roundsAbout Amprion
Developer of a test designed to detect pathological α-synuclein in cerebrospinal fluid. The company provides autopsy-confirmed diagnostic accuracy, enabling clinicians to make biologically informed decisions for neurodegenerative diseases such as Parkinson's, Lewy body dementia, and Alzheimer's.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2007
- Employees
- 39
- Website
- ampriondx.com/
- Ownership
- Privately Held (backing)
Amprion doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Amprion shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Amprion in its N-PORT filings yet. We sweep new filings monthly.